Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Tenax Therapeutics, Inc. (TENX) provides access to the company’s official disclosures as a Nasdaq-listed, Phase 3, development-stage pharmaceutical company. Through these filings, Tenax reports material events, clinical and corporate milestones, and periodic financial results related to its cardiopulmonary drug development programs.
Recent Form 8-K filings have documented key developments in the company’s PH-HFpEF program. These include announcements that the European Patent Office issued an Intention to Grant a patent covering TNX‑103 (oral levosimendan), other levosimendan formulations, and its active metabolites for use in PH-HFpEF, and that Tenax completed a prespecified blinded sample size re-estimation in the registrational Phase 3 LEVEL trial of TNX‑103 in the United States and Canada. Other 8‑K filings describe the initiation of the global Phase 3 LEVEL‑2 study and amendments to the company’s license agreement with Orion Corporation, expanding Tenax’s rights to develop, commercialize, and manufacture orally administered levosimendan products.
Filings also include earnings-related 8-Ks, where Tenax furnishes press releases detailing quarterly financial results and corporate updates. These disclosures discuss research and development spending on the LEVEL and LEVEL‑2 trials, general and administrative expenses, and the company’s cash position and funding outlook, all within the framework of SEC reporting requirements.
On this page, users can review Tenax’s SEC submissions, including current reports and other documents that may be filed over time. Stock Titan enhances this information with AI-powered summaries that explain the significance of complex filings, highlight clinical and IP milestones, and help readers quickly identify items related to Phase 3 trial progress, licensing arrangements, and the company’s PH-HFpEF strategy. This resource supports investors and researchers seeking a structured view of TENX’s regulatory and financial reporting history.
Tenax Therapeutics, Inc. has called its Annual Meeting of Stockholders for June 2, 2026 at 9:00 a.m. Eastern Time at its Chapel Hill, North Carolina headquarters. Stockholders of record as of April 8, 2026, when 25,775,500 common shares were outstanding, may vote.
Investors will elect seven directors for one-year terms and vote on ratifying Cherry Bekaert LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board states that all director nominees are recommended for election and unanimously recommends a “FOR” vote on the auditor ratification.
The proxy explains in detail how to vote by Internet, telephone, mail, or in person, describes quorum and broker non-vote treatment, and outlines board structure, committee composition, independence determinations, and executive pay, including salary, bonuses, and significant stock option awards for the CEO and other named executives.
Tenax Therapeutics is appointing Thomas R. Staab, II as Chief Financial Officer effective May 11, 2026, replacing interim CFO Thomas McGauley after the company files its Quarterly Report for the quarter ended March 31, 2026. Mr. McGauley will continue as a consultant through at least the end of May 2026.
Under an executive employment agreement, Mr. Staab will receive a $428,000 annual base salary and a target bonus equal to 45% of salary, plus inducement equity awards of 10,000 restricted stock units and options to purchase 450,000 shares of common stock, with multi‑year vesting and severance protections of nine to twelve months’ salary, bonus and COBRA reimbursements depending on termination circumstances.
TENAX THERAPEUTICS, Inc. Schedule 13G/A amendment shows Morgan Stanley reporting combined operating units with shared voting and dispositive power in the low hundreds of thousands of shares and ownership below 5%.
The filing lists Morgan Stanley with shared voting power 592,504 and shared dispositive power 596,564 (reported 3.5%), and Morgan Stanley Capital Services LLC with shared voting and dispositive power 583,297 (reported 3.4%). The filing states both entities have ceased to be beneficial owners of more than five percent of the class. Signatures are dated 04/08/2026.
Tenax Therapeutics, Inc. reporting persons Ikarian Capital, LLC and Neil Shahrestani state beneficial ownership of 1,145,100 shares of Common Stock, representing 6.7% of the class. The filing notes 127,500 shares may be acquired within 60 days pursuant to options and cites 17,197,613 shares outstanding as of March 6, 2026 from the company's Form 10-K.
The statement is a joint Schedule 13G/A describing indirect beneficial ownership through Ikarian-managed funds and accounts, with shared voting and dispositive power reported. The filing includes standard disclaimers about group status and beneficial‑ownership attribution.
Tenax Therapeutics filed a shelf registration to offer up to $300,000,000 of common stock, preferred stock, debt securities, warrants, rights or units. The prospectus is a shelf offering dated March 24, 2026 and states offerings may occur from time to time after effectiveness.
The document states the company will specify terms in prospectus supplements and that the company intends to use net proceeds for general corporate purposes, including advancing its Phase 3 levosimendan programs (LEVEL and LEVEL-2).
Tenax Therapeutics CEO Christopher Thomas Giordano has filed a Schedule 13D reporting a 6.79% beneficial ownership stake in the company’s common stock. He is deemed to beneficially own 1,252,965 shares, based on 17,197,613 shares outstanding as of March 6, 2026.
The position consists of 2,605 shares of common stock and 1,250,360 shares underlying stock options with various exercise prices. Giordano states he holds the shares for investment purposes and may buy or sell additional shares over time, but has no current plans to change control or the company’s corporate structure.
Tenax Therapeutics, Inc. files its annual report as a Phase 3, development-stage pharma company focused on cardiopulmonary diseases, led by oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
The company is running two global Phase 3 trials, LEVEL and LEVEL-2, targeting 6‑minute walk distance and quality-of-life endpoints, with open-label extensions to build the long-term safety database regulators requested. Imatinib (TNX-201) for pulmonary arterial hypertension is retained but deprioritized.
Tenax strengthened its balance sheet with a $25.0 million private placement in March 2025 and about $100.0 million raised in August 2024, reporting $97.6 million in cash and cash equivalents as of December 31, 2025. The business model depends on successful Phase 3 outcomes, regulatory approvals, and future commercialization or partnerships under an exclusive levosimendan license from Orion.
Tenax Therapeutics reported 2025 results and highlighted major progress in its Phase 3 program for levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (PH-HFpEF). The company reached its randomization target of 230 patients in the Phase 3 LEVEL trial and expects topline data in the third quarter of 2026. A second global registrational Phase 3 study, LEVEL-2, began in December 2025, with enrollment anticipated to complete by the end of 2027, and an open-label extension will allow continued TNX-103 access.
Cash and cash equivalents were $97.6 million as of December 31, 2025, and Tenax expects this to fund operations through 2027. R&D expenses rose to $10.5 million for the fourth quarter and $32.7 million for the full year 2025, compared with $4.6 million and $12.7 million in 2024, mainly due to advancing LEVEL and initiating LEVEL-2. G&A expenses increased to $5.9 million for the quarter and $23.7 million for the year, versus $2.7 million and $6.8 million in 2024, largely from higher stock-based compensation and professional fees. Net loss widened to $15.5 million for the quarter and $52.6 million for 2025, compared with $6.3 million and $17.6 million in 2024.